ftp.xmission.com/2014.06.ftp.xmission.com.tar/ftp.xmission.com/pub/lists/associates/archive/v01.n011

Internet Message Format | 1999-09-05 | 14KB

From: [e-mail] (associates-digest)
To: [e-mail]
Subject: associates-digest V1 #11
Reply-To: associates-digest
Sender: [e-mail]
Errors-To: [e-mail]
Precedence: bulk


associates-digest      Monday, September 6 1999      Volume 01 : Number 011



(associates) HP labs at forefront of nanotechnology article
(associates) Weekend Nanogirl News~

----------------------------------------------------------------------

Date: Fri, 3 Sep 1999 15:43:42 -0700
From: "Gina Miller" <[e-mail]>
Subject: (associates) HP labs at forefront of nanotechnology article

See this nano/url

"Brilliant New World" article

http://www.hp.com/ghp/features/nano/index.html

Gina "Nanogirl" Miller
Nanotechnology Industries
Web: http://www.nanoindustries.com
Personal website:
http://www.homestead.com/nanotechind/nothingatall.html
Get the Nanotechnology Industries newsletter at:
http://www.homestead.com/nanonews/describe.html
E-mail: [e-mail]
"Nanotechnology: solutions for the future."


- -
 To unsubscribe from associates, send an email to "[e-mail]"
 with "unsubscribe associates" in the body of the message.
 For information on digests or retrieving files and old messages send
 "help" to the same address.  Do not use quotes in your message.

------------------------------

Date: Sun, 5 Sep 1999 21:38:18 -0700
From: "Gina Miller" <[e-mail]>
Subject: (associates) Weekend Nanogirl News~

Weekend Nanogirl news~Tidbits to tide you over

*To see more concerning Hewlett Packards Stan Williams and his research
involving nanometer-scale structures for computing and communications: pi=
ck
up the Sept-Oct issue of "MIT's Magazine of Innovation TECHNOLOGY Review.=
"
There is a 4 page articles called "Computing after Silicon" with an
interview on Williams theories on nanometer-scaled components cheaply and
easily assembled using simple chemistry. You can aquire the issue at your
local newstand/bookstore or go to MIT's web site.

*Image of Electron Orbitals Confirms Controversial Bonding Hypothesis. Us=
ing
a combination of convergent beam electron diffraction and X-ray diffracti=
on
techniques, a team of materials researchers at Arizona State University h=
ave
achieved startlingly clear images of electron orbitals responsible for
bonding in Cu2O, also known as cuprite, a ceramic semiconductor with a ra=
re
structure.
http://clasdean.la.asu.edu/news/cuprite.htm

*Virginia Tech Researchers Create New Family Of Molecule, Solve Fullerene
Processing Mystery
BLACKSBURG, Aug. 30, 1999 -- Leaky lab equipment and Virginia Tech
researchers' eagle eyes have resulted in a new family of molecules with
potential applications ranging from medicine to optical-electronic device=
s,
and beyond. The researchers report in the Sept. 2, 1999, issue of Nature
that they can produce C80 fullerenes containing three metal atoms
("Small-bandgap endohedral metallofullerenes in high yield and purity").
http://fbox.vt.edu:10021/ur/news/Archives/Aug99/99348.html

* Wistar Institute Scientists Find Key Piece In Gene Regulation Puzzle
Philadelphia -- For the first time, scientists working in The Wistar
Institute laboratory of Ronen Marmorstein, PhD, in collaboration with
Shelley Berger, PhD, have determined the three-dimensional structure of a
key enzyme involved in gene activation.
http://www.wistar.upenn.edu/internet/new_site/pr_pages/pr_9.99_2.html

*Order Chemical Reviews special thematic issue:Nanostructures July 1999.
http://pubs.acs.org/journals/chreay/thematic/99/nanostructure.html

*For decades, pharmaceutical companies have struggled to overcome the
molecular equivalent of the Great Wall of China: the outer membrane of
cells, which prevents all but the tiniest of proteins from entering. Now
researchers have slipped a protein that's more than 200 times larger than
the average drug into the cells of living mice and shown that the protein
functions.
http://medicine.wustl.edu/~wumpa/news/dowdyprotein.html

*Scientists at Jefferson Medical College have found a way to isolate
hard-to-find hematopoietic stem cells. The researchers, in identifying a
chemical beacon =96 a protein marker =96 on the cell, believe the new wor=
k will
lead to laboratory production of all types of blood cells for transfusion=
s
and innovative approaches for bone marrow transplants and gene therapy.
http://www.jeffersonhealth.org/news/1999/083199.html

*Loss of Molecular Handbrakes Compromises Immune System. Two related
proteins that act as brakes for a variety of cellular growth processes
appear to play a critical role in ensuring that both blood cells and immu=
ne
system cells are neither overactive nor overabundant. One of the proteins
may play a role in the development of certain types of leukemia.
http://www.hhmi.org/news/ihle.htm

*OSU Medical Center uses robotic heart surgery technique
A new minimally invasive heart surgery technique utilizing robotic
technology has been performed at The Ohio State University Medical Center.
It was the first use in North America of the da Vinci Computer-Enhanced
Surgical System which uses sensitive remote-controlled surgical instrumen=
ts
guided by a surgeon at a computer keyboard.
http://www.acs.ohio-state.edu/units/research/archive/1stsurg.htm

*Cloning gives second chance for bull. A calf has been cloned from a
21-year-old celebrity bull, the oldest animal yet reproduced using this
technology.
http://news.bbc.co.uk/hi/english/sci/tech/newsid_437000/437391.stm

*Genetic finds get smarter, faster Sydney Morning Herald)
Gene breakthroughs that could lead to ways to boost intelligence, extend =
our
life span, and cure diabetes were among many genetic findings announced i=
n
international journals this week.
http://www.smh.com.au/news/9909/04/text/national13.html

*New Scientist book review of: The Making of Intelligence by Ken Richards=
on,
Weidenfeld & Nicolson.
http://www.newscientist.com/ns/19990904/whatmakesu.html

*DNA traces humble origins of noble wines.A grape variety once banned as
inferior and unworthy is actually the ancestor of some of France=92s most
highly prized wines, says a researcher who analyzed the genetic history o=
f
grapes from such legendary wine centers as Champagne and Burgundy.
http://www.msnbc.com/news/307475.asp

*A man with muscular dystrophy has been injected with genes for a needed
muscle protein, a method which may find success in treating the disease.
http://abcnews.go.com/sections/living/DailyNews/md_genetherapy990903.html

*God Welcome in Biologist's Lab
Religion and science aren't mutually exclusive in Francisco J. Ayala's
universe. He's an evolutionary biologist and an ordained priest. Ayala
believes in God even as he stands stooped over in his laboratory, jugglin=
g
beakers and breeding new kinds of fruit flies.
http://www.latimes.com/excite/990904/t000079131.html

*Everyone's guide to DNA Computers.
http://dna2z.com/dnacpu/dne.html

*Read the letter that the American Society for Cell Biology wrote to the
Governor of Kansas in response to the recent ruling by that state's Board=
 of
Education regarding the teaching of evolution.
http://www.faseb.org/ascb/

*Future riches may lie in genes Companies with potential to revolutionise
health care set to be stockmarket stars.  WHEN the first biotechnology
companies went public in the 1980s, US stockbrokers likened the investmen=
t
opportunity to buying [ Xerox ] or IBM at its initial public offering. So
when the genomics firms tapped the public markets a decade later, it was =
no
surprise that the analogy that brokers made was to [ Microsoft ] . There =
may
be more than a germ of truth to this genomics pitch. If you believe that
some companies have the potential to create a new industry, or to alter t=
he
rules for an existing one, then those are stocks to own for the long term.
The thesis behind the genomics companies is that deciphering all the gene=
s
that make up the human genome, or the sum of the body's genetic informati=
on,
will prompt huge changes in health care. In this vision, gene-based
diagnostic tests will predict disease years or decades before it occurs, =
and
drugs of extraordinary specificity will prevent or cure illnesses such as
cancer, heart disease and stroke - without side effects. The leading drug
companies have already paid hundreds of millions of dollars to the genomi=
cs
firms to gain access to their data, and the betting is that the health-ca=
re
system will one day pay billions for genomics-based drugs. The shares may=
 be
volatile, and investors may want to use big movements as trading
opportunities, but basically, those who believe the thesis may want to ow=
n
them almost regardless of how expensive they become. And those who do not
believe it, of course, may want to stay away. Shares of two of the bigges=
t
gene merchants have been on a tear as investors have reacted to several
gene-related discoveries announced by Maryland-based [ Human Genome
Sciences ] . Shares in Human Genome, the early player and the only one to
take its own drugs into clinical trial, are up more than 80 per cent sinc=
e
January 1. They closed on Wednesday at US$71.375 more than three times th=
eir
52-week low of $22.75 last September. The stock of [ Millennium
Pharmaceuticals ] , based in Massachusetts, has tended to follow that of
Human Genome, even though Millennium has yet to develop drugs of its own.
But it has reaped more than $1 billion from corporate partnerships and pl=
ans
to acquire a drug later this year. At its closing price of $62.50 on
Wednesday it has more than doubled since January 1 and is up sixfold from
its low last September. The other two big genomics stocks are in companie=
s
that sell genetic data-bases to big drug companies.
In comparison to those in the first category, their shares seem like valu=
e
stocks. Celera Genomics Group Maryland was spun off from [ PE Corp ] at
$21.31 a share in May. It closed on Wednesday at $30.625. Shares of Incyt=
e
Pharmaceuticals of California closed at $28.25 on Wednesday down more tha=
n
20 per cent since January, largely because of the perception that an
independent Celera poses a threat to its core business. Michael Murphy,
editor of the California Technology Stock Letter, recommends a basket of
Human Genome, Incyte and Celera. "Own all three, because what you want to=
 do
here is get a position in what will clearly be the basis of medicine in t=
he
21st century," he said. He thinks Human Genome could hit $150 by 2002 but
has not established targets for the others. Mr Murphy excludes Millennium
because it has diversified into agriculture and diagnostic sectors, and h=
e
no longer sees it as a pure genomics play. But that assessment is not
universal. Viren Mehta, an analyst with Mehta Partners, a health-care sto=
ck
research firm, thinks Millennium has the best business model for both
finding partners and prospering on its own. "What is important to remembe=
r
is that up to now, the majority of drug discovery successes of smaller
companies had to be shared with larger companies," he said.
"It is quite likely the future will be no different." Most big-selling dr=
ugs
are pills, which must be based on small molecules produced through medici=
nal
chemistry, province of the big drug firms.
"Millennium has chosen to first establish a robust scientific
infrastructure, and from there to create very lucrative partnerships, whe=
re
a substantial portion of the combined success will still become the
exclusive property of Millennium," Mr Mehta said. "If you are going to bu=
y
one stock and put it away for your grandchildren, which will it be? We ha=
ve
recommended Millennium for a long time."
But other analysts say Millennium's future remains dependent on the succe=
ss
of its partners or the acquisition of a compound that may become a
successful drug, for which it will have to compete with the same
deep-pocketed companies it partners with. Human Genome Sciences is alone
among the genomics companies in having created drugs - three of them, all
undergoing clinical trials. "We tend to favour companies that not only
supply genes or data bases to corporate partners but, most importantly, c=
an
develop their own drugs," said Anthony Butler, an analyst with [ Lehman
Brothers ] , which took Human Genome public in 1992. "It's amazing what j=
ust
one drug will do for your value," Mr Butler said.
The New York Times (Copyright 1999)

Gina "Nanogirl" Miller
Nanotechnology Industries
Web:
http://www.nanoindustries.com
E-mail:
[e-mail]
Alternate E-mail
[e-mail]
"Nanotechnology: solutions for the future."
Get the Nanotechnology Industries newsletter at:
http://www.homestead.com/nanonews/describe.html
Personal home pages at:
http://www.homestead.com/nanotechind/nothingatall.html






- -
 To unsubscribe from associates, send an email to "[e-mail]"
 with "unsubscribe associates" in the body of the message.
 For information on digests or retrieving files and old messages send
 "help" to the same address.  Do not use quotes in your message.

------------------------------

End of associates-digest V1 #11
*******************************

-
 To unsubscribe from $LIST, send an email to "[e-mail]"
 with "unsubscribe $LIST" in the body of the message.
 For information on digests or retrieving files and old messages send
 "help" to the same address.  Do not use quotes in your message.